Sheryl Stevenson

Kenneth C. Fan, MD, discusses promising visual improvements from MCO-010 therapy for Stargardt disease at AAO 2025, highlighting future treatment potential.

Research on aflibercept 8 mg reveals promising real-world outcomes for treating wet AMD and diabetic macular edema, enhancing vision and safety.

Stephen Tsang, MD, PhD, reviews promising optogenetic therapy results for retinitis pigmentosa and Stargardt disease, enhancing vision and mobility for patients.

Ophthalmologists weigh in on how the extended-duration therapy may reduce treatment burden for patients with wet age-related macular degeneration.

Retina specialists share their perspectives on evolving anti-VEGF therapy, pipeline treatments, and strategies to enhance patient outcomes.

A new study reveals a promising drug reduces vision loss in Stargardt disease, showing significant safety and efficacy over 2 years.

While the STAR trial showed significant reductions in myopia progression, including over 50% in fast-progressing children, the FDA requires additional evidence to support US approval.

Gildeuretinol has also been evaluated in atrophic age-related macular degeneration, said Philip J. Ferrone, MD

The newest research findings create "tangible benchmarks" for how earlier treatment can lead to better outcomes, said Dr. Kim.

The topical therapy offers a less invasive approach to corneal cross-linking, with commercial availability anticipated in early 2026.

Dr. Singh reported that when technicians understand why they are performing a diagnostic test, they perform better and think critically in patient care situations.

AAO attendees can preview the new technician training platform on Sunday, October 19.

The video-driven platform will improve workflow, education and engagement, said Inder Paul Singh, MD.

Phase 1/2 interim results highlight real-world functional enhancements in patients with severe LCA5-related Leber congenital amaurosis.

NASA’s development of autonomous eye imaging technologies for astronauts aboard the International Space Station is paving the way for remote, high-quality eye care both in deep space and underserved regions on Earth.

Five years after the COVID-19 pandemic shutdown reshaped how the world gathers, here's how some of ophthalmology’s leading associations are still applying lessons forged in crisis.

The 15th annual meeting, taking from March 24–28 in Snowmass, Colorado, will deliver high-impact discussions on macular disease, artificial intelligence in ophthalmology, and breakthrough therapies—plus opportunities for networking on and off the slopes.

A single lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, is being voluntarily recalled by Alcon Laboratories due to the detection of fungal material in a consumer-reported vial.

Ferhina S. Ali, MD, discussed the real-world efficacy and durability of next-generation anti-VEGF agents like faricimab and aflibercept 8 mg, emphasizing how large-scale data offers insights into their performance and safety beyond clinical trials.

Vaidehi S. Dedania, MD, from the New York University (NYU) Langone Health and the Grossman School of Medicine, spoke with the Eye Care Network at this year's AAO meeting held in Chicago, Illinois. She insights from the session, "Preventing and managing complications following vitreoretinal surgery."

Vikas Chopra, MD, from the Doheny Eye Institute of UCLA, caught up with the Eye Care Network at this year's AAO meeting held in Chicago, Illinois. He shared how technology has advanced ophthalmic surgery over the years and how hands on sessions at the meeting allow surgeons to train for rare complications that can arise during routine surgeries.

Alfredo Sadun, MD, PhD, is the chief of Ophthalmology at the Doheny Eye Institute of UCLA. At this year's AAO meeting held in Chicago, Illinois, he stopped by the Eye Care Network booth to share insights from the symposium "Professional Longevity 2.0: Assessing the Ophthalmologist," which he presented during.

Valerie Biousse, MD, from the Emory University in Atlanta, Georgia, shared insights on how ocular imaging in the emergency department can provide timely, accurate diagnosis while also benefiting the on-call ophthalmologists.

In a paper presented at the American Academy of Ophthalmology annual meeting in Chicago, Jonathan Tan, a third year medical student at the Icahn School of Medicine at Mount Sinai detailed the study on ophthalmic eye drop waste in clinics, revealing 72% medication loss due to outdated 28-day expiration guidelines, resulting in significant financial waste. The study advocates following FDA expiration dates.

Jonathan Brugger, MD, shared insights on the correlation of central retinal vein occlusions, or branch retinal vein occlusions, in young adults who consume numerous energy drinks.

Glenn C. Yiu, MD, PhD, from the University of California David, shared insights from his presentation on suprachoroidal drug delivery in the real world at this year's AAO meeting held in Chicago, Illinois.

Henderson’s presentation touches on the shift in medical education from traditional learning to AI and robotics.

During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr., MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.

In a presentation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Lu, MD, a retina specialist at Johns Hopkins Medicine, discussed the application of large language models (LLMs) in revenue cycle management (RCM).

Michael Singer, MD, shared insights from on his experience using a preservative-free, chloroprocaine ophthalmic gel as anesthesia for intravitreal injections and the results of research on the effectiveness of gel versus traditional drops.